Immunotherapy in oncogene addicted non-small cell lung cancer

The use of immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) has led to notable changes in treatment strategies for patients with advanced non-small cell lung cancer (NSCLC) and now forms a part of standard of care treatment i...

Descripción completa

Detalles Bibliográficos
Autores principales: McLean, Luke, Leal, Jose Luis, Solomon, Benjamin J., John, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Lung Cancer and The Immune System
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264320/
https://www.ncbi.nlm.nih.gov/pubmed/34295674
http://dx.doi.org/10.21037/tlcr-20-772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264320/
https://www.ncbi.nlm.nih.gov/pubmed/34295674
http://dx.doi.org/10.21037/tlcr-20-772

Ejemplares similares